Enara Bio has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to research and develop novel targeted cancer immunotherapies.
The partnership will provide additional funding to advance Dark Antigen research, further independent validation of Enara’s novel EDAPT™ platform, and brings a wealth of big pharma development resources to help drive discoveries into the clinic.
Key features of the deal include:
- Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports the ongoing cell therapy based therapeutic approach
- Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
- Enara Bio will receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumour type explored
- Enara Bio is eligible to receive more than €876M in clinical, regulatory and commercial milestones, in addition to royalties on future product sales
- Partnership strengthens Boehringer Ingelheim’s position in the cancer vaccine and T‐cell engager spaces
‘We’re excited to be partnered with an innovation-led company that has built considerable expertise in cancer vaccines and immune-oncology.’
Kevin Pojasek, CEO Enara Bio.
Enara Bio is an SV Health backed start-up, originally named Ervaxx, that was founded in 2016 using technology developed at the Francis Crick Institute, London.
The company joined the BioEscalator in 2018 with 5 employees and through connections including, immunopeptidomics expert Dr Nicola Ternette of University of Oxford and Dr Adrian Hill of University of Oxford and Vaccitech, has developed 2 proprietary platforms and grown the team to over 20. Enara is currently in the process of expanding operations and relocating to The Oxford Science Park.
Boehringer Ingelheim is a family owned pharmaceutical company based in Ingelheim, Germany. It is the world’s largest privately held pharmaceutical company which focuses on innovation to benefit both human and animal health.